Skip to main content

RT @Yuz6Yusof: #LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in

Jun 04, 2022 7:30 am
Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×